The 21st century has seen great advances in biotechnology and other fields. But some things still remain elusive, such as getting a cure for cancer. There are many research centers and clinics that are trying to find a cure for the menace. Hearing that one of the local research centers has already found a treatment for lymphomas is excellent news. The man behind the achievement is none other than Clay Siegall and his company Seattle Genetics.
Clay Siegall started this company in 1998 after working in several biotechnology firms. When he started the company, it was a small outfit with a handful of workers. However, close to two decades later, he has a drug that has already been approved by the FDA, a great team and more than 12 other drugs that are in testing.
Siegall has managed to create a drug that has so far been successful in treating more than 20 types of myelomas. The sales of the company were great in the first year after the FDA approved the drug. The company netted $250 million. In addition to the drug being sold locally, it has also been approved for sale in 60 other countries. In Canada, the sale of the drug is assisted by Takeda pharmaceuticals. According to the latest projections, the drug will make sales of $320 million in the coming financial year.
In the wake of these developments, the company has found it necessary to change the way things work. The first step they have taken is to hire more workers to meet their growing demands. They are looking for 100 more workers that will help with the research connected to the other 12 drugs. One of the drugs that are in testing has already been found to be quite effective in treating lymphomas.
The company has also been listed on NASDAQ, which means that people who invest in shares can now own a piece of this great biotech company. These and other positive changes are probably the reason why even the vice president himself, Joe Bidden gave a visit to the company. One can only expect bigger and better things from them.
Learn more about Clay Siegall: